Edition:
United Kingdom

Sonoma Pharmaceuticals Inc (SNOA.OQ)

SNOA.OQ on NASDAQ Stock Exchange Capital Market

3.82USD
18 May 2018
Change (% chg)

$0.02 (+0.53%)
Prev Close
$3.80
Open
$3.79
Day's High
$3.82
Day's Low
$3.79
Volume
4,637
Avg. Vol
19,701
52-wk High
$7.75
52-wk Low
$3.50

Select another date:

Tue, Apr 17 2018

BRIEF-Sonoma Pharma Receives Four New Uae Regulatory Approvals That Include Acne And Anti-Fungal Products

* SONOMA PHARMACEUTICALS RECEIVES FOUR NEW UAE REGULATORY APPROVALS THAT INCLUDE ACNE AND ANTI-FUNGAL PRODUCTS

BRIEF-Sonoma Pharmaceuticals Announces FDA Approval For Antimicrobial Post Therapy Gel

* ANNOUNCES FDA APPROVAL FOR ANTIMICROBIAL POST THERAPY GEL Source text for Eikon: Further company coverage:

BRIEF-Montreux Equity Partners Reports 9.26 Pct Passive Stake In Sonoma Pharmaceuticals

* MONTREUX EQUITY PARTNERS REPORTS 9.26 PERCENT PASSIVE STAKE IN SONOMA PHARMACEUTICALS AS OF MARCH 2 - SEC FILING Source text: (http://bit.ly/2FvWSFR) Further company coverage:

BRIEF-Sonoma Pharmaceuticals Closes $5 Million Public Offering

* SONOMA PHARMACEUTICALS ANNOUNCES CLOSING OF $5 MILLION PUBLIC OFFERING OF COMMON STOCK

BRIEF-Sonoma Pharmaceuticals Announces Pricing Of $5 Mln Public Offering Of Common Stock

* SONOMA PHARMACEUTICALS ANNOUNCES PRICING OF $5 MILLION PUBLIC OFFERING OF COMMON STOCK

BRIEF-Sonoma Pharma Revenue $4.8 Million For Third Quarter

* SONOMA PHARMACEUTICALS REPORTS RECORD TOTAL REVENUE OF $4.8 MILLION FOR THIRD QUARTER FY 2018 WITH YEAR OVER YEAR PRODUCT REVENUE GROWTH OF 46%

BRIEF-Sonoma Pharma Gets Three New UAE Regulatory Approvals

* SONOMA PHARMACEUTICALS RECEIVES THREE NEW UNITED ARAB EMIRATES REGULATORY APPROVALS: ACUICYN® FOR MANAGEMENT OF BLEPHARITIS, MICROSAFE® ORAL CARE FOR MUCOSITIS AND SINUDOX® FOR CHRONIC SINUSITIS

BRIEF-Sonoma Pharmaceuticals announces second FDA approval to add antimicrobial language to alevicyn gel products

* SONOMA PHARMACEUTICALS ANNOUNCES SECOND FDA APPROVAL TO ADD ANTIMICROBIAL LANGUAGE TO ALEVICYN™ GEL PRODUCTS FOR MANAGEMENT OF ATOPIC DERMATITIS Source text for Eikon: Further company coverage:

Select another date: